CLEC4C and systemic lupus erythematosus: Based on the critical role of pDCs in aberrantly secreting type I interferons and pro-inflammatory cytokines in SLE pathogenesis, researchers have developed BDCA2-ADC (DB-2304), which utilizes a novel Immune Modulating Antibody Conjugate (DIMAC) platform to couple a glucocorticoid with an anti-BDCA2 antibody, achieving highly selective delivery to pDCs.